BlackRock
CYCN icon

BlackRock’s Cyclerion Therapeutics CYCN Stock Holding History

BlackRock’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26K Hold
16,797
– – ﹤0.01% 5255
2025
Q4 		$21.3K Hold
16,797
– – ﹤0.01% 5207
2025
Q3 		$38.6K Hold
16,797
– – ﹤0.01% 5023
2025
Q2 		$48.9K Hold
16,797
– – ﹤0.01% 4992
2025
Q1 		$42K Hold
16,797
– – ﹤0.01% 4950
2024
Q4 		$54.1K Hold
16,797
– – ﹤0.01% 4931
2024
Q3 		$43.5K Sell
16,797
-372
-2% -$1.09K ﹤0.01% 4840
2024
Q2 		$39.5K Hold
17,169
– – ﹤0.01% 4907
2024
Q1 		$54.9K Hold
17,169
– – ﹤0.01% 4853
2023
Q4 		$57.5K Sell
17,169
-831
-5% -$2.4K ﹤0.01% 4942
2023
Q3 		$61.6K Hold
18,000
– – ﹤0.01% 4966
2023
Q2 		$74.2K Sell
18,000
-1
-0% -$5 ﹤0.01% 4998
2023
Q1 		$156K Sell
18,001
-14
-0.1% -$177 ﹤0.01% 4846
2022
Q4 		$236K Sell
18,015
-19
-0.1% -$225 ﹤0.01% 4804
2022
Q3 		$310K Sell
18,034
-45
-0.2% -$773 ﹤0.01% 4859
2022
Q2 		$198K Sell
18,079
-3,990
-18% -$57.2K ﹤0.01% 5031
2022
Q1 		$490K Sell
22,069
-189
-0.8% -$4.55K ﹤0.01% 4871
2021
Q4 		$765K Buy
22,258
+500
+2% +$23.6K ﹤0.01% 4746
2021
Q3 		$1.34M Sell
21,758
-49
-0.2% -$3.21K ﹤0.01% 4480
2021
Q2 		$1.7M Sell
21,807
-62,467
-74% -$3.91M ﹤0.01% 4344
2021
Q1 		$4.7M Buy
84,274
+4,068
+5% +$306K ﹤0.01% 3969
2020
Q4 		$4.91M Buy
80,206
+4,039
+5% +$275K ﹤0.01% 3717
2020
Q3 		$9.26M Sell
76,167
-2,176
-3% -$249K ﹤0.01% 3261
2020
Q2 		$9.26M Sell
78,343
-1,120
-1% -$93.6K ﹤0.01% 3223
2020
Q1 		$4.21M Sell
79,463
-1,371
-2% -$97.8K ﹤0.01% 3426
2019
Q4 		$4.4M Buy
80,834
+5,361
+7% +$501K ﹤0.01% 3547
2019
Q3 		$18.3M Buy
75,473
+1,586
+2% +$343K ﹤0.01% 2861
2019
Q2 		$16.9M Buy
+73,887
New +$20.9M ﹤0.01% 2940

Other funds holding CYCN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

BlackRock's CYCN Position: Q1 2026 in Review

BlackRock held its Cyclerion Therapeutics (CYCN) position steady in Q1 2026 at 16,797 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #5255.

BlackRock first reported a position in CYCN in Q2 2019 and has held it in 28 quarters since. The position peaked at $18.3M in Q3 2019. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • BlackRock held 16,797 shares of Cyclerion Therapeutics worth $26K as of Q1 2026.
  • BlackRock left its Cyclerion Therapeutics share count unchanged in Q1 2026.
  • Cyclerion Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #5255 holding.
  • BlackRock first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • BlackRock's Cyclerion Therapeutics position peaked at $18.3M in Q3 2019.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.